Early laboratory research counsel {that a} Covid-19 antibody remedy developed by GlaxoSmithKline PLC and Vir Biotechnology Inc. is efficient towards the Omicron variant, the businesses stated, setting it other than comparable therapies that seem to work much less effectively towards the extremely mutated pressure.
The businesses stated Thursday that that they had examined the drug, known as sotrovimab, towards sure particular person mutations present in Omicron, which has now been detected in at the least 24 international locations, together with the U.S. Glaxo and Vir stated the findings had been preliminary and they’d want to check the remedy towards the entire of the mutated spike protein discovered within the variant to verify the outcome. The businesses printed the preliminary analysis, which hasn’t but been peer reviewed.
